Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers

Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma

(2016) Yongdong Liu et al.   BIOMEDICINE & PHARMACOTHERAPY

Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo

(2016) E. M. Kosciuczuk et al.   BLOOD

The therapeutic potential of mTOR inhibitors in breast cancer

(2016) Linda S. Steelman et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

4E-BP1, a multifactor regulated multifunctional protein

(2016) Xiaoyu Qin et al.   CELL CYCLE

Small-molecule kinase inhibitors: an analysis of FDA-approved drugs

(2016) Peng Wu et al.   DRUG DISCOVERY TODAY

Targeting translation: eIF4E as an emerging anticancer drug target

(2016) Chunwan Lu et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Unveiling new chemical scaffolds as Mnk inhibitors

(2016) Sarah Diab et al.   Future Medicinal Chemistry

nanoCAGE reveals 5′ UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs

(2016) Valentina Gandin et al.   GENOME RESEARCH

Epigenetic regulators and their impact on therapy in acute myeloid leukemia

(2016) F. Pastore et al.   HAEMATOLOGICA

Elevated levels of p-Mnk1, p-eIF4E and p-p70S6K proteins are associated with tumor recurrence and poor prognosis in astrocytomas

(2016) Weibing Fan et al.   JOURNAL OF NEURO-ONCOLOGY

Tuning Specific Translation in Cancer Metastasis and Synaptic Memory: Control at the MNK–eIF4E Axis

(2016) Clive R. Bramham et al.   TRENDS IN BIOCHEMICAL SCIENCES

TORC2 Structure and Function

(2016) Christl Gaubitz et al.   TRENDS IN BIOCHEMICAL SCIENCES

TOR Complexes and the Maintenance of Cellular Homeostasis

(2016) Sandra Eltschinger et al.   TRENDS IN CELL BIOLOGY

mTORC1 and CK2 coordinate ternary and eIF4F complex assembly

(2016) Valentina Gandin et al.   Nature Communications

CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway

(2016) Qiuyuan Wen et al.   Oncotarget

eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma

(2016) Ting Liu et al.   Oncotarget

Epigenetic polypharmacology: from combination therapy to multitargeted drugs

(2016) Angel R. de Lera et al.   Clinical Epigenetics

Epigenetic regulators and their impact on therapy in acute myeloid leukemia

(2016) F. Pastore et al.   HAEMATOLOGICA

Characterization of MNK1b DNA Aptamers That Inhibit Proliferation in MDA-MB231 Breast Cancer Cells

(2016) Eva M García-Recio et al.   Molecular Therapy-Nucleic Acids

The MAP kinase-interacting kinases regulate cell migration, vimentin expression and eIF4E/CYFIP1 binding

(2015) James E. Beggs et al.   BIOCHEMICAL JOURNAL

Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells

(2015) S C Thumma et al.   CANCER GENE THERAPY

Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells

(2015) Theodosia Teo et al.   CANCER LETTERS

Differential Requirements for eIF4E Dose in Normal Development and Cancer

(2015) Morgan L. Truitt et al.   CELL

Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma

(2015) Krystyna Mazan-Mamczarz et al.   Cell Communication and Signaling

mTOR coordinates protein synthesis, mitochondrial activity and proliferation

(2015) Masahiro Morita et al.   CELL CYCLE

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

(2015) T. J. Galloway et al.   CLINICAL CANCER RESEARCH

An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis

(2015) Theodosia Teo et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

eIF4F: A Retrospective

(2015) William C. Merrick   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting the translation machinery in cancer

(2015) Mamatha Bhat et al.   NATURE REVIEWS DRUG DISCOVERY

Architecture of human mTOR complex 1

(2015) C. H. S. Aylett et al.   SCIENCE

Current treatment strategies for inhibiting mTOR in cancer

(2015) Francesca Chiarini et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Targeting Mnks for Cancer Therapy

(2015) Jinqiang Hou et al.   Oncotarget

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

(2014) Zheng Zhao et al.   ACS Chemical Biology

mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling

(2014) Huiyuan Zhang et al.   APOPTOSIS

Probing the Binding Mechanism of Mnk Inhibitors by Docking and Molecular Dynamics Simulations

(2014) Srinivasaraghavan Kannan et al.   BIOCHEMISTRY

MAP Kinase-Interacting Kinases—Emerging Targets against Cancer

(2014) Sarah Diab et al.   CHEMISTRY & BIOLOGY

Discovery of 5-(2-(Phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation

(2014) Sarah Diab et al.   ChemMedChem

Multifunctional compounds: Smart molecules for multifactorial diseases

(2014) Yogita Bansal et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas

(2014) Michal Grzmil et al.   JOURNAL OF CLINICAL INVESTIGATION

A review on pharmacophoric designs of antiproliferative agents

(2014) Anil Rana et al.   MEDICINAL CHEMISTRY RESEARCH

MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma

(2014) E. K. Slotkin et al.   MOLECULAR CANCER THERAPEUTICS

Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3

(2014) N Robichaud et al.   ONCOGENE

Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors

(2014) Hiren Patel et al.   MedChemComm

Adaptation to chronic mTOR inhibition in cancer and in aging

(2013) Rebecca Gilley et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors

(2013) J. K. Altman et al.   BLOOD

Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a)

(2013) Rebecca L. Stead et al.   FEBS LETTERS

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation

(2013) Claire L. Cope et al.   JOURNAL OF CELL SCIENCE

mTOR kinase structure, mechanism and regulation

(2013) Haijuan Yang et al.   NATURE

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

(2013) Jiri Polivka et al.   PHARMACOLOGY & THERAPEUTICS

Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity

(2013) K. Feoktistova et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Insights into the Importance of DFD-Motif and Insertion I1 in Stabilizing the DFD-Out Conformation of Mnk2 Kinase

(2013) Jinqiang Hou et al.   ACS Medicinal Chemistry Letters

mTOR inhibitors in cancer therapy

(2012) Yekaterina Y. Zaytseva et al.   CANCER LETTERS

Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1

(2012) Chuanbing Zang et al.   CANCER LETTERS

eIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies

(2012) T. Alain et al.   CANCER RESEARCH

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

New perspectives on the biology of fragile X syndrome

(2012) Tao Wang et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

The mTOR Signalling Pathway in Human Cancer

(2012) Helena Pópulo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Kinome-wide Selectivity Profiling of ATP-competitive Mammalian Target of Rapamycin (mTOR) Inhibitors and Characterization of Their Binding Kinetics

(2012) Qingsong Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition

(2012) A Astanehe et al.   ONCOGENE

EMT as the ultimate survival mechanism of cancer cells

(2012) Neha Tiwari et al.   SEMINARS IN CANCER BIOLOGY

Translational Control in Cancer Etiology

(2012) D. Ruggero   Cold Spring Harbor Perspectives in Biology

Translation initiation factors and active sites of protein synthesis co-localize at the leading edge of migrating fibroblasts

(2011) Mark Willett et al.   BIOCHEMICAL JOURNAL

mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling Pathways

(2011) P. Gulhati et al.   CANCER RESEARCH

Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases

(2011) B. W. Konicek et al.   CANCER RESEARCH

MAP Kinase-Interacting Kinase 1 Regulates SMAD2-Dependent TGF-  Signaling Pathway in Human Glioblastoma

(2011) M. Grzmil et al.   CANCER RESEARCH

Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells

(2011) Michal Marzec et al.   PLoS One

A Perspective on Cancer Cell Metastasis

(2011) C. L. Chaffer et al.   SCIENCE

Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+-De novo Ceramide-PP2A-Reactive Oxygen Species-Dependent Signaling Pathway

(2010) M. A. Park et al.   CANCER RESEARCH

Targeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer

(2010) A. C. Hsieh et al.   CLINICAL CANCER RESEARCH

Discovery of Mitogen-Activated Protein Kinase-Interacting Kinase 1 Inhibitors by a Comprehensive Fragment-Oriented Virtual Screening Approach

(2010) Julen Oyarzabal et al.   JOURNAL OF MEDICINAL CHEMISTRY

Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells

(2010) Fei-fei Zhou et al.   MEDICAL ONCOLOGY

Cell adhesion: integrating cytoskeletal dynamics and cellular tension

(2010) J. Thomas Parsons et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development

(2010) T. Ueda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression

(2010) L. Furic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mnk earmarks eIF4E for cancer therapy

(2010) N. Hay   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets

(2009) Nahum Sonenberg et al.   CELL

Translational control of eukaryotic gene expression

(2009) Katrien Van Der Kelen et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

PIKKing on PKB: regulation of PKB activity by phosphorylation

(2009) Lana Bozulic et al.   CURRENT OPINION IN CELL BIOLOGY

mTOR and cancer: many loops in one pathway

(2009) Alejo Efeyan et al.   CURRENT OPINION IN CELL BIOLOGY

Promise and challenges in drug discovery and development of hybrid anticancer drugs

(2009) Lalji K Gediya et al.   Expert Opinion on Drug Discovery

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy

(2008) J. R. Graff et al.   CANCER RESEARCH

Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells

(2008) Andrea Bianchini et al.   CARCINOGENESIS

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

(2008) T. H. Luu et al.   CLINICAL CANCER RESEARCH

Moving targets: cell migration inhibitors as new anti-inflammatory therapies

(2008) Charles R Mackay   NATURE IMMUNOLOGY